Baseline characteristics and their associations with methotrexate monotherapy
| Methotrexate monotherapy | Combination therapy | Univariate | Multivariate | |
|---|---|---|---|---|
| (n=493) | (n=238) | Odds ratio (95% CI) | Odds ratio (95% CI) | |
| Female | 326 (66) | 161 (68) | 0.97 (0.70–1.36) | 1.26 (0.78–2.05) |
| Age (years) | 61 (49–70) | 56 (45–68) | 1.01* (1.00–1.03) | 1.02* (1.01–1.04) |
| Disease duration (weeks) | 29 (17–49) | 29 (17–51) | 1.00 (0.99–1.01) | 1.00 (0.99–1.01) |
| RF positive (IU/ml) | 195 (40) | 115 (48) | 0.60* (0.43–0.85) | 0.44* (0.29–0.68) |
| CRP (mg/l) | 6 (3–18) | 6 (3–18) | 1.00 (0.99–1.00) | 0.99 (0.98–1.00) |
| HAQ score | 1 (0.5–1.625) | 1 (0.5–1.625) | 1.03 (0.83–1.29) | 0.94 (0.66–1.33) |
| DAS28 | 5.12 (3.95–6.13) | 4.88 (3.89–6.15) | 1.02 (0.91–1.14) | 1.09 (0.92–1.30) |
| >1 comorbidity | 310 (63) | 149 (63) | 1.01 (0.73–1.39) | 0.74 (0.46–1.18) |
| Smoking status | ||||
| Current | 109 (22) | 48 (20) | 1.27 (0.84–1.93) | 1.31 (0.74–2.34) |
| Previous | 192 (39) | 81 (34) | 1.33 (0.93–1.89) | 0.89 (0.54–1.48) |
| Never | 189 (38) | 106 (45) | ref | ref |
| Year of recruitment | ||||
| 2009–2010 | 43 (9) | 11 (5) | ref | ref |
| 2011–2012 | 227 (46) | 116 (49) | 0.50 (0.25–1.01) | 0.37 (0.16–0.87) |
| 2013–2014 | 223 (45) | 111 (47) | 0.51 (0.26–1.04) | 0.37 (0.16–0.89) |
Data are presented as n (%) for categorical variables and median (IQR) for quantitative variables.
↵* p<0.01.